Effect of sodium zirconium cyclosilicate on potassium lowering for 28 days among outpatients with hyperkalemia: the HARMONIZE randomized clinical trial.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Hyperkalemia is a common electrolyte abnormality that may be difficult to manage because of a lack of effective therapies. Sodium zirconium cyclosilicate is a nonabsorbed cation exchanger that selectively binds potassium in the intestine.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): JAMA

Title: JAMA

ISSN (Electronic): 1538-3598

ISSN (Print): 0098-7484

Publication date (Electronic): Dec 3 2014

Volume: 312

Issue: 21

Affiliations

[1 ] Saint Luke's Mid America Heart Institute, Kansas City, Missouri2University of Missouri-Kansas City.

[2 ] ZS Pharma, Coppell, Texas.

[3 ] Boston Biostatistics Research Foundation, Framingham, Massachusetts.

[4 ] University of Texas Health Science Center at San Antonio.

[5 ] Weill Medical College of Cornell University, New York, New York.

[6 ] Melbourne Renal Research Group and Department of Medicine, University of Melbourne, Melbourne, Australia.

[7 ] Renal Research, Gosford, Australia.

[8 ] Xelay Acumen, Belmont, California.

[9 ] University of Illinois at Chicago College of Medicine, Chicago11Advocate Christ Medical Center, Oak Lawn, Illinois.

Article

Publisher Item ID: 1936753

DOI: 10.1001/jama.2014.15688

PubMed ID: 25402495

SO-VID: fff70abd-d17f-4fee-b127-730b3b823a08

History

Data availability:

Effect of sodium zirconium cyclosilicate on potassium lowering for 28 days among outpatients with hyperkalemia: the HARMONIZE randomized clinical trial.

Read this article at

Abstract

Related collections

JAMA Network: Coronavirus

Author and article information

Journal

Affiliations

Article

History

Comments

Comment on this article

Cited by 118